Novo Nordisk to invest €432m in Athlone manufacturing site
Novo Nordisk will invest €432m in its Athlone, Ireland, tabletting plant to add manufacturing capacity for current and future oral GLP-1 therapies.
Image modified: Novo Nordisk
SynAct Pharma appoints Ann Kristin Led as CFO
SynAct Pharma has named Ann Kristin Led as CFO, effective 1 March 2026. The finance executive brings experience across life sciences, pharma and med-tech.
Evinova integrates Citeline data into AI-native Study Designer
Evinova is integrating Citeline’s Sitetrove and Trialtrove data into its AI-native Study Designer to support faster, data-driven clinical trial design.
Xspray Pharma appoints Blake Leitch as CEO, Per Andersson to become CSO
Xspray Pharma has appointed Blake Leitch as CEO, with the start date no later than June 1, 2026. Current CEO Per Andersson will become CSO.
GSK agrees to acquire 35Pharma, adding pulmonary hypertension asset HS235
GSK has agreed to acquire Canada’s 35Pharma for $950m in cash, gaining HS235, an activin signalling inhibitor being developed for pulmonary hypertension.
Novo Nordisk partners with Vivtex on oral biologics
Novo Nordisk and Vivtex will work on oral biologics for obesity and diabetes. Vivtex is eligible for up to US$2.1 billion plus tiered royalties.
Fresenius extends CEO Michael Sen’s contract to 2031, appoints Pawlu to the Management Board
Fresenius extends CEO Michael Sen’s contract early, taking it through 2031. Helios executive Christian Pawlu will join the Management Board on July 1, 2026.
Merck reshapes business ahead of Keytruda patent expiry
Merck & Co. is splitting operations into two divisions to prepare for Keytruda’s 2030 patent expiry and to broaden its portfolio.
Ad Alliance rolls out cross-media campaign for blend-a-dent
Ad Alliance has implemented a cross-media campaign for P&G’s blend-a-dent, combining BRIGITTE and Meins co-branding with RTL and VOX TV placements.
Roche appoints Mark Dawson to lead pRED
Roche names Mark Dawson as Head of Pharma Research and Early Development from 1 May 2026 and adds him to the Enlarged Corporate Executive Committee.